Open-label infliximab therapy in Crohns disease: a long-term multicenter study of efficacy, safety and predictors of response
Gastroenterol. hepatol. (Ed. impr.)
; 31(7): 421-426, ago. 2008. tab
Article
in En
| IBECS
| ID: ibc-70196
Responsible library:
ES15.1
Localization: ES15.1 - BNCS
ABSTRACT
BACKGROUND: Efficacy of infliximab in Crohns disease(CD) showed by randomized controlled trials must beconfirmed in clinical practice. We aimed to evaluate efficacyand safety of infliximab in CD patients of the Madrid area,looking for clinical predictors of response.METHODS: Multicenter retrospective survey of all CD patientstreated with infliximab in 8 University hospitals of theMadrid area (Spain) with a minimum follow up of 14wks.RESULTS: 169 patients included (48%males, mean age 39 ±12 yrs). 64% of them had perianal disease. 82% were underimmunosuppressants. 1355 infliximab infusions administered(mean 8, range 1-30). 90% response rate and 48%remission rate were obtained with induction therapy. 73%followed maintenance treatment, and 78% of them maintainedor improved the response after a mean follow up of 28months (range 3.5-86). 24 patients lost response during thefollow up, after a mean of 41wks (range 6-248). Only theprescription of maintenance therapy was predictive factorfor favourable response (p < 0.01). 17 infusion reactionswere reported (10% of the patients, 1.2% of the infusions;only one case was severe) and were the cause of treatmentwithdrawal in 7 patients. Co-treatment with immunosuppressivedrugs and maintenance infliximab therapy wereprotective factors for infusion reactions (p < 0.05). Other adverseevents occurred in 26% of the patients, and were causeof treatment withdrawal in 7 patients.CONCLUSIONS: Infliximab is effective and safe for CD managementbut concomitant immunosuppressive drugs andmaintenance treatment should be prescribed to obtain thebest outcome. That confirms in a real life clinical setting the favourable results obtained in randomized clinical trials (AU)
Search on Google
Collection:
06-national
/
ES
Database:
IBECS
Main subject:
Crohn Disease
/
Antibodies, Monoclonal
Type of study:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
Gastroenterol. hepatol. (Ed. impr.)
Year:
2008
Document type:
Article